Last Updated on: 16/11/2026
Nishamalaki for Patients with Type 2 Diabetes Mellitus
Nishamalaki has been described in Uttara Sthana of Ashtanga Hridayam. It is a combination of amla (Emblica officinalis) and haridra (Curcuma longa) mixed in equal quantities. According to Standard treatment guidelines on the management of metabolic disorders in Ayurveda system of medicine, Ministry of AYUSH, Government of India, nishamalaki is considered as one among the drugs of choice for the management of patients with type 2 diabetes mellitus. In order to validate the claims, we went looking ahead for the research evidence in favour of/against the use of nishamalaki for patients with type 2 diabetes mellitus.
We searched pubmed and google scholar as the database for the research articles. Paid databases were not part of the search. Only the first five pages of Google scholar were searched for relevant articles with the search term nishamalaki.
Search strategy followed for pubmed was ((((((Nishamalaki[Title/Abstract]) OR (haldi[Title/Abstract])) OR (amalaki[Title/Abstract])) OR (curcuma longa[Title/Abstract])) OR (emblica officinalis[Title/Abstract])) AND ((((((((Randomied controlled trial[Title/Abstract]) OR (Clinical trial[Title/Abstract])) OR (Prospective trial[Title/Abstract])) OR (case series[Title/Abstract])) OR (pre post study[Title/Abstract])) OR (observational study[Title/Abstract])) OR (controlled trial[Title/Abstract])) OR (real world trial[Title/Abstract]))) AND ((((((((Type 2 diabetes mellitus[MeSH Terms]) OR (diabetes mellitus[Title/Abstract])) OR (metabolic disorder[Title/Abstract])) OR (Prameha[Title/Abstract])) OR (Madhumeha[Title/Abstract])) OR (sugar[Title/Abstract])) OR (hyperglycemia[Title/Abstract])) OR (hypoglycemia[Title/Abstract])) 05/11/2026 at 16:50 PM IST).
Nishamalaki – Characteristics of Included Studies
| Authors/Study Design | Study Title | Diagnosis | Duration/Groups/Numbers | Intervention |
|---|---|---|---|---|
| Punchihewa T.K.G. et al., 2021 Single group, Immediate Effects | Evaluation of the acute effect of Nishamalaki Churna in the management of blood glucose level in diabetes mellitus type 2 | T2DM | Immediate Effects (OGTT) A: 10 Data: 0, 10 min, 30 min, 60 min & 90 min weeks | A: Nishamalaki 5g stat in 100ml of lukewarm water (Amla and Haldi 1:1 ratio) |
| Damle N. 2021 Single group pre-post study | Clinical study to evaluate the efficacy of Nisha Amalaki churna in newly diagnosed Prameha type II diabetes mellitus | T2DM | 3 Months A: 10 Data: 0, 30, 60, 90 days | A: Nishamalaki Churna 3g BD before breakfast and dinner with warm water (Amla and Haldi 1:1 ratio) |
| Sawita A.W. A Case Report | Nisha-amalaki in uncontrolled type 2 diabetes mellitus-A case report | T2DM | 8 Weeks A: 1 Data: 0, 4, 8 weeks | A: Nishamalaki churna with warm water in early morning + Metformin + Glimipiride (Amla and Haldi 1:1 ratio) |
| Munshi R. et al., 2023 RCT | A randomized, controlled, comparative, proof-of-concept study to evaluate the efficacy and safety of Nisha-Amalaki capsules in prediabetic patients for preventing progression to diabetes | Prediabetes | 6 Months A: 30 B: 28 Data: 0, 3, 6 Months | A: Nishamalaki Extract Capsule 500mg 1BD after food B: Maltodextrin 500mg BD after food (Amla and Haldi 2:1 ratio) |
| Khatiwada N. et al., 2026 Comparative Trial | A Comparative Study of Effectiveness of Triphaladi Kwath and Nishamalaki Churna in the Management of Madhumeha | T2DM | One Month A: 25 B: 25 Data: 0, 1 Month | A: Triphaladi Kwath B: Nishamalaki Churna |
| Sija M.U. et al., 2017 Comparative Clinical Trial | Efficacy of vidanga Rajanyadi kashaya and Nishamalaki churna in the management of Prameha wsr to NIDDM: A clinical trial | NIDDM | 30 Days A: 15 B: 15 Data: 0, 30 Day | A: Vidanga Rajanyadi Kashaya 50ml BD half an hour before food B: Nishamalaki Churna 6g BD half an hour before food with warm water |
| Yadav R.K., 2001 Comparative Study | Clinical trial of an indgenous compound drug nishaamalki in the management of madhumeha vis-à-vis diabetes mellitus | Madhumeha (NIDDM) | For 45 Days A: 25 B: 25 Data: 0, 15 & 30 days | A: Barley Powder 1g TDS B: Nishamalaki 1g BD (Amla and Haldi 1:1 ratio) |
| Namade G.V. et al., 2022 Comparative Study | A comparative clinical study to evaluate the efficacy of vidangadi loha and nishamalaki churna in the management of madhumeha wsr to diabetes mellitus type-2 | T2DM | 90 Days A: 20 B: 20 Data: 0, 30, 90, 120 Days | A: Vidangadi Loha 250mg BD after food with honey B: Nishamalaki Churna 1g BD before food with warm water |
The pubmed search strategy yielded 17 results. The reference list of relevant articles was further checked to look for missing articles. A total of 37 articles were compiled after combining pubmed, google scholar and reference lists of relevant articles. One article was removed from the list after checking for duplication. Screening resulted in further removal of 28 articles due to non-relevance. Finally 8 research articles were considered for the review.
Out of these 8 studies, seven studies have focussed on type 2 diabetes mellitus (T2DM) or non insulin dependent diabetes mellitus (NIDDM) and one study has targeted patients with prediabetes. Apart from nishamalaki, studies have looked for the impact of vidangadi loha, vidangadi rajanyadi kashaya and triphaladi kwath on patients with T2DM as a comparison with nishamalaki. Out of a total eight studies, there were four comparative studies, two single group pre-post studies, one case report. Another one study was a randomized controlled trial which focussed on patients with prediabetes.
References:
1) Standard treatment guidelines on the management of metabolic disorders in the ayurveda system of medicine. Ministry of AYUSH, Govt. of India. https://www.yamc.yenepoya.edu.in/PDF/STG%20Ayuveda_Metabolic%20Disorders.pdf (Google Search on 16.11.2026 at 15:16)
2) Punchihewa, T. K. G., Ekneligoda, R. V., & Uyanege, P. P. (2021). Evaluation of the acute effect of Nishamalaki Churna in the management of blood glucose level in diabetes mellitus type 2. Int J Sci Res Eng Dev, 4(1). https://ijsred.com/volume4/issue1/IJSRED-V4I1P104.pdf (Google search on 18.11.2026 at 12:30PM)
3) Damle, N. (2021). Clinical study to evaluate the efficacy of Nisha Amalaki churna in newly diagnosed Prameha type II diabetes mellitus. Indian J Appl Res, 11(3), 42-43. https://www.researchgate.net/publication/350946331_CLINICAL_STUDY_TO_EVALUATE_EFFICACY_OF_NISHA_AMALAKI_CHURNA_IN_NEWLY_DIAGNOSED_PRAMEHA_TYPE_II_DIABETES_MELLITUS (Google search on 8.11.2026 at 12:31PM)
4) Arjun, W. S., Rashmi, P., & KK, M. N. (2022). Nisha-amalaki in uncontrolled type 2 diabetes mellitus-A case report. https://www.researchgate.net/publication/360349376_Nisha-Amalaki_in_Uncontrolled_Type_2_Diabetes_Mellitus-_A_Case_Report (Google search on 18.11.2026 at 12:32PM)
5) Munshi, R., Karande-Patil, S., Kumbhar, D., Deshmukh, A., & Hingorani, L. (2023). A randomized, controlled, comparative, proof-of-concept study to evaluate the efficacy and safety of Nisha-Amalaki capsules in prediabetic patients for preventing progression to diabetes. Journal of Ayurveda and Integrative Medicine, 14(6), 100806.
6) Khatiwada, N., & Singh, B. K. (2025). A Comparative Study of Effectiveness of Triphaladi Kwath and Nishamalaki Churna in the Management of Madhumeha. Journal of Ayurveda Doctors Association of Nepal, 11(1), 25-32.
7) Sija, M. U., Acharya, S., & Naveen, K. (2017). Efficacy of vidanga Rajanyadi kashaya and Nishamalaki churna in the management of Prameha wsr to NIDDM: A clinical trial. Muniyal Institute of Ayurvedic Medical Sciences, Manipal, Karnataka, India.
8) Yadav, R. K., Mishra, R., Chhipa, R. P., & Audichya, K. C. (2001). Clinical trial of an indigenous compound drug nishaamalki in the management of madhumeha vis-à-vis diabetes mellitus. Ancient science of life, 21(1), 18-24.
9) Namade, G. V., & Adi, A. M. (2022). A comparative clinical study to evaluate the efficacy of vidangadi loha and nisha amalaki churna in the management of madhumeha w.s.r. diabetes mellitus type 2. International Journal of Creative Research Thoughts, 10(10), d667-d678. https://ijcrt.org/viewpaperforall.php?paper=IJCRT2210424
